XERS
Xeris Pharmaceuticals Inc
NASDAQ: XERS · HEALTHCARE · BIOTECHNOLOGY
$6.13
+1.74% today
Updated 2026-04-30
Market cap
$1.04B
P/E ratio
0.00
P/S ratio
3.56x
EPS (TTM)
$0.00
Dividend yield
—
52W range
$4 – $10
Volume
1.9M
Xeris Pharmaceuticals Inc (XERS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-16.09M | $-24.66M | $-56.28M | $-104.35M | $-80.56M | $-95.53M | $-102.89M | $-47.02M | $-36.98M | $28.63M |
| Capital expenditures | $35000.00 | $700000.00 | $1.51M | $1.11M | $377000.00 | $1.08M | $524000.00 | $2.26M | $868000.00 | $696000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $540000.00 | $499000.00 | $1.73M | $6.48M | $8.27M | $11.38M | $12.16M | $10.72M | $18.36M | $22.37M |
| Free cash flow | $-16.12M | $-25.36M | $-57.79M | $-105.45M | $-80.94M | $-96.62M | $-103.42M | $-49.29M | $-37.85M | $27.93M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $60.68M | $95.64M | $25.09M | $147.05M | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $3.67M | $-26.20M | $18.08M | — | — | — | — | — |